Evogene Business Summary

Evogene Ltd. (EVGN) operates as a computational chemistry pioneer utilizing its proprietary ChemPass AI™ engine to design and optimize novel small molecules for the life sciences industry. The company generates revenue through a partnership-driven business model that includes R&D collaborations, licensing agreements, and milestone-based payments, primarily serving the Human Health (Pharma) and Agriculture (Ag-chemicals) segments. Following a 2025 strategic pivot, Evogene streamlined its operations by divesting non-core assets—such as the sale of Lavie Bio to ICL—to focus on high-value generative AI discovery for synthesizable drug candidates and sustainable crop protection. Its primary competitors include Cibus Inc., Novonesis, and Precision BioSciences; within this landscape, Evogene distinguishes itself as a capital-efficient technology hub that provides highly optimized, multi-parameter molecular designs to global industry leaders like Bayer, Corteva, and Google Cloud. Originally established in 2002 as a spin-off from Compugen Ltd., Evogene was co-founded by Dr. Hagai Karchi and Dr. Rafi Meissner to apply genomic expertise to agricultural biotechnology. The current leadership is spearheaded by President and CEO Ofer Haviv, a Certified Public Accountant and former Treasurer of Compugen who has led the company since 2004. Technical and strategic development is overseen by Dr. Ilia Zhidkov, VP of Computational Platform, and Dr. Gabi Tarcic, VP of Product, while the finance function is transitioning to Polina Ravzin following the planned departure of CFO Yaron Eldad in March 2026. The company’s board is chaired by Nir Nimrodi, an Operating Partner at Archimed, and includes notable members such as Sarit Firon of Team8 and veteran investor Leon Recanati. Evogene maintains a diverse institutional investor base featuring firms such as Citadel Advisors, Jane Street Group, and Morgan Stanley.